A neat summary from CEO David Atkins, which explains the mistakes of the previous team, all of whom have now been replaced... and the improved commercialisation pathway that he is implementing.
Colostat is in the final stages of validation, preparing for NATA Lab-based approval.
Genetype already has NATA Lab-based approval.
https://**promotion blocked**/health/biocurious-rhythm-gets-into-the-groove-of-predicting-and-preventing-cancer/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
-0.005(3.70%) |
Mkt cap ! $36.93M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 15.0¢ | 13.0¢ | $307.0K | 2.202M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 201700 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 7090 | 1 |
View Market Depth
| Last trade - 10.46am 07/08/2025 (20 minute delay) ? |
| RHY (ASX) Chart |